Leading Edge Clinic DART-TINN DMSO dual-route tinnitus study

Single-arm pilot of compounded dual-route DMSO therapy for refractory subjective tinnitus, combining an otic solution with betahistine, dexamethasone, and lidocaine plus a transdermal cream with levocarnitine and N-acetylcysteine.

Verified only as a Leading Edge Clinic-sponsored registry study record. ClinicalTrials.gov lists Leading Edge Clinic as the non-industry lead sponsor and Rebuild Medicine Inc as a collaborator of unknown class. This remains a small, open-label, single-arm compounded-therapy pilot, so present it as a low-confidence study-level record rather than a validated product program.